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Abstract: Maintaining bone health is important for patients with breast cancer (BC), the most 
commonly diagnosed cancer in American women. Indeed, bone loss is common throughout 
the BC disease continuum. In the metastatic BC setting, patients are likely to develop bone 
metastases, a painful complication that can lead to potentially debilitating skeletal-related 
events. Bone health is equally important for patients with early BC. During adjuvant therapy 
for early BC, the largest challenge to bone health is from accelerated bone mineral density 
(BMD) loss. Although decreased BMD is well recognized in older, postmenopausal women, 
it may be underestimated in younger, premenopausal women undergoing endocrine therapy 
for BC. The rate and extent of cancer therapy-induced bone loss (from chemotherapy or endo-
crine therapy) are substantially greater than normal decreases in BMD during menopause. 
Bisphosphonates such as zoledronic acid (ZOL) are antiresorptive agents indicated for the 
treatment of bone metastases from BC. Clinical trials over the past few years suggest that, 
although not yet approved for this indication, ZOL can prevent cancer therapy-induced bone 
loss and improve BMD in premenopausal women receiving adjuvant (endocrine or chemo-) 
therapy for BC. Furthermore, the benefits of ZOL therapy may go beyond maintaining bone 
health and include potential anticancer benefits together with favorable tolerability and cost/
benefit profiles. This review will focus specifically on the role of ZOL in preserving the bone 
health of premenopausal women with BC.
Keywords: breast cancer, premenopausal, zoledronic acid
Introduction
Breast cancer (BC) is the most commonly diagnosed cancer among American women.1 
Indeed, in 2010 it was estimated that in the USA 207,090 women were diagnosed 
with BC and 39,840 women died from the disease.1 Following surgical resection of 
the tumor, patients with BC receive adjuvant therapy, which includes chemotherapy 
(eg, taxanes, anthracyclines, cyclophosphamide-methotrexate-fluorouracil) and hor-
monal therapy. Challenges to bone health common in patients with BC include bone 
metastases in advanced disease and bone loss due to adjuvant therapies (endocrine 
suppression and chemotherapy) in early disease.
Bone disease in advanced BC
Bone metastases develop in 65% to 75% of patients with advanced BC,2,3 regardless of 
menopausal status. Interactions between BC cells and cells that regulate bone metabo-
lism result in a vicious cycle leading to increased cancer growth and spread of bone 
metastases and bone loss.3 Metastatic bone disease in BC is a painful complication 
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characterized by elevated rates of localized osteolysis, which 
can lead to potentially debilitating skeletal-related events 
(SREs).3 All SREs (ie, pathologic fracture, spinal cord com-
pression, radiotherapy to bone, hypercalcemia of malignancy, 
and surgery to bone) are associated with decreased quality 
of life, but pathologic fractures are also associated with 
decreased survival.4,5
Bone disease in early BC
Adjuvant therapy for early BC causes accelerated bone 
mineral density (BMD) loss, especially in premenopausal 
patients. Bone is maintained through a continuous remodel-
ing process involving resorption of existing bone by osteo-
clasts and formation of new bone by osteoblasts. Estrogen 
and normal estrogen receptor function help maintain this 
coupled and balanced process. Decreased estrogen levels 
due to natural menopause or artificial menopause, caused 
by chemotherapy-induced ovarian failure or ovarian sup-
pression, are detrimental to bone health as reduced estrogen 
levels can lead to bone loss.6
Ovarian suppression or selective estrogen receptor 
modulators are used to treat premenopausal women with 
hormone-receptor-positive BC.7 Ovarian ablation causes 
immediate, artificial menopause, and chemotherapy can lead 
to ovarian failure. Subsequently, estrogen levels decrease 
dramatically, resulting in increased osteoclast-mediated bone 
resorption and subsequent BMD decrease.8–10 Tamoxifen, 
although bone-sparing in postmenopausal women or when 
used concurrently with ovarian suppression, is associated 
with bone loss when used as monotherapy in premenopausal 
patients.11 Although decreased BMD is well recognized in 
older, postmenopausal women, it may be underestimated in 
younger, premenopausal women receiving adjuvant therapy 
for BC. The rate and extent of cancer therapy-induced bone 
loss (CTIBL) are more than twofold greater than normal 
decreases in BMD during menopause, suggesting that tra-
ditional antiosteoporosis doses of bisphosphonates (BPs) 
might be insufficient to counter CTIBL.9,10,12
Antiresorptive therapies are used to prevent CTIBL 
associated with adjuvant BC therapy. Nitrogen-containing 
bisphosphonates (N-BPs) such as zoledronic acid (ZOL) 
and pamidronate are indicated for the treatment of bone 
metastases from BC.13,14 Numerous clinical studies have 
demonstrated that, in addition to their established roles in 
the metastatic setting, BPs can preserve BMD in patients 
receiving adjuvant therapy for BC.9,10,15–20 This review will 
focus specifically on the role of ZOL in preserving the bone 
health of premenopausal women with BC.
Zoledronic acid mechanisms  
of action
All BPs are antiresorptive, bone-targeted agents that induce 
apoptosis in osteoclasts. Non-nitrogen-containing BPs 
(ie, clodronate) are metabolized into nonhydrolyzable, 
cytotoxic analogues of adenosine triphosphate.21 In contrast, 
N-BPs (eg, ibandronate, pamidronate, ZOL) inhibit farnesyl 
diphosphate (FPP) synthase, a key enzyme in the mevalonate 
pathway. This important biochemical pathway is involved 
in the production of cholesterol and isoprenoids, which are 
required for maintaining cell membrane integrity, producing 
steroids, and regulating cellular respiration.22 Inhibition of 
FPP synthase leads to impaired prenylation and subcellular 
localization of G-proteins, consequently reducing the function 
of Ras family proteins (small signaling molecules involved in 
a range of cellular functions).23,24 Furthermore, FPP synthase 
inhibition also impedes signal transduction and triggers osteo-
clast apoptosis.25,26 In preclinical studies, ZOL was the most 
potent FPP synthase inhibitor among N-BPs evaluated and 
also demonstrated the greatest antiresorptive activity.23
Preserving bone health
Advanced BC
Antiresorptive agents such as BPs and denosumab reduce 
the risk of skeletal complications in patients with metastatic 
BC, regardless of menopausal or hormone receptor status.27,28 
Pamidronate and ZOL are well-established BPs with long-term 
tolerability and efficacy profiles (first approved by the United 
States Food and Drug Administration in 1991 and 2001, respec-
tively).13,14,29 Pamidronate and ZOL are indicated for the treat-
ment of malignant bone disease in patients with BC or multiple 
myeloma.13,14 However, ZOL is also indicated for the treatment 
of bone metastases from prostate cancer and other solid tumors, 
in addition to BC.13 Denosumab, a monoclonal antibody against 
the receptor activator of nuclear factor-κB ligand, is a newer 
antiresorptive agent also indicated for the treatment of bone 
metastases from solid tumors, including BC but not multiple 
myeloma.27 Several clinical trials have demonstrated the efficacy 
of antiresorptive agents (BPs and denosumab) for delaying the 
onset of SREs in patients with advanced BC.28,30,31 Accordingly, 
the American Society of Clinical Oncology and the National 
Comprehensive Cancer Network have specifically updated their 
guidelines to recommend ZOL, pamidronate, and denosumab 
for patients with advanced BC.32,33
Early BC
Antiresorptive agents preserve BMD by blocking bone 
resorption by osteoclasts. Although BPs are not indicated 
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in the United States for the prevention of CTIBL in patients 
with BC, a number of studies have shown that these agents 
are effective for maintaining BMD during adjuvant therapy 
for BC in premenopausal women (Table 1).9,10,17–20,34 Thus 
far, the effects of denosumab on BMD have not been studied 
specifically in premenopausal women with BC, although 
it has been shown to be effective in preventing bone loss 
in postmenopausal women with osteoporosis or receiving 
aromatase inhibitors for early BC.35,36 Similarly, ZOL has 
also demonstrated efficacy for preventing bone loss in these 
patient populations.37–40 However, several studies also have 
shown ZOL to be effective for preserving or improving BMD 
in premenopausal women with early BC.
For example, in one trial with premenopausal women 
receiving adjuvant chemotherapy for early stage BC, 101 
patients were randomized to receive intravenous (IV) ZOL 
(4 mg every 3 months) or placebo.17 At 12 months, patients 
who received ZOL had stable BMD while those who received 
placebo experienced BMD loss at the lumbar spine (-4.1%) 
and total hip (-2.6%; P , 0.0001).17 Furthermore, this benefit 
with ZOL was maintained 1 year after completion of ZOL 
treatment. Patients who received placebo continued to experi-
ence declining BMD at the lumbar spine (-6.3%) and total 
hip (-2.6%) through 24 months, compared with stable BMD 
at both sites in patients who received ZOL (P , 0.0001).18
The Cancer and Leukemia Group B 79809 trial is another 
study that examined the effects of ZOL on CTIBL from 
chemotherapy-induced ovarian failure in premenopausal 
women. In this study, premenopausal women with stage 1–3 
BC (n = 439) were randomized to receive ZOL (IV 4 mg 
every 3 months for 2 years) either early (within 3 months 
of randomization) or late (1 year after randomization).10 
In patients with baseline and 1-year BMD measurements 
(n = 302), early ZOL treatment (ie, started with chemo-
therapy) prevented CTIBL and significantly increased BMD 
above baseline levels (+1.4%) compared with no ZOL 
(-5.5%; P , 0.001).10 Although tamoxifen therapy was 
associated with more modest BMD loss than chemotherapy 
alone in patients who did not receive ZOL, CTIBL was not 
completely attenuated. In a subset of women who developed 
Table 1 Trials of bisphosphonates for prevention of bone loss in premenopausal women receiving adjuvant endocrine therapy for 
breast cancer
Bisphosphonate N Dose Results
PAM16 40 60 mg Iv Q3M for 9 mo Preserved baseline BMD at 1-y follow-up  
↓ LS bone loss vs placebo at 1 y (P = 0.002)
CLO67 73 1600 mg/day PO for 3 y Preserved baseline BMD at 3-y follow-up 
↓ LS bone loss vs placebo at 5 y (P = 0.008)
CLO34 148 1600 mg/day PO for 2 y ↓ LS bone loss vs no CLO at 2 y  
(-2.2% vs -5.9%; P = 0.0005) 
Preserved BMD at FN vs no CLO at 2 y  
(+0.9% vs -2.0%; P = 0.017)
CLO20 311 1600 mg/day PO for 2 y ↑ BMD at the LS and TH vs placebo at 1 y 
(2.38% and 0.74%, respectively) and 2 y  
(1.72% and 1.85%, respectively)
RIS15 53 8 × 12-wk cycles  
(30 mg/day × 2 wk and no treatment × 10 wk)
Preserved baseline LS BMD at 2-y follow-up  
(-0.2% vs -2.5%)
RIS41 216 35 mg/wk PO Failed to prevent CTIBL at 1-y follow-up  
for RIS vs placebo  
(n = 170; -4.3% vs -5.4%)
ZOL17,18 101 4 mg Iv Q3M for 12 mo Preserved baseline BMD vs placebo  
(P , 0.0001; LS BMD -5.5% at 12 mo  
and -6.3% at 24 mo with placebo)
ZOL19 112 4 mg Iv Q6M for 1 y ↓ bone loss vs no ZOL at 1 y (-1.1% vs -7.5%;  
P , 0.001)
ZOL9 404 4 mg Iv Q6M for 3 y ↑ LS BMD vs baseline at 3 y (+0.4%) and 5 y  
(+4.0%; P = 0.02) 
No ZOL ↓ LS BMD vs baseline at 3 y  
(-11.3%; P , 0.0001) and 5 y (-6.3%; P = 0.001)
ZOL10 439 4 mg Iv Q3M for 2 y ↑ BMD vs placebo at 1 y  
(+1.2% vs -6.7%, respectively; P , 0.001)
Abbreviations: BMD, bone mineral density; CLO, clodronate; CTIBL, cancer therapy induced bone loss; FN, femoral neck; Iv, intravenous; LS, lumbar spine; mo, months; N, 
number; P, probability level; PAM, pamidronate; PO, oral; Q3M, every 3 months; Q6M, every 6 months; RIS, risedronate; TH, total hip; vs, versus; wk, weeks; ZOL, zoledronic 
acid; y, years; ↑, indicates increase; ↓, indicates decrease.
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chemotherapy-induced ovarian failure at 1 year (n = 150), 
early ZOL treatment prevented CTIBL and significantly 
increased BMD above baseline levels (+1.2%) compared with 
no ZOL therapy (-6.7%; P , 0.001).10 At 3 years, 1 year after 
completion of 2 years of ZOL therapy, patients who received 
early ZOL maintained increased BMD (+1.0%) versus base-
line, compared with those who received late ZOL (1 year 
of no ZOL followed by 1 year of ZOL, -0.5%; P = 0.019). 
Notably, ZOL improved BMD in this patient population 
regardless of concomitant tamoxifen therapy.
A bone substudy of the Austrian Breast and Colorectal 
Cancer Study Group trial 12 (ABCSG-12) examined the 
effects of ZOL on BMD in premenopausal women receiving 
adjuvant endocrine therapy (ovarian blockade with goserelin 
plus tamoxifen or anastrozole) for BC. In this substudy, pre-
menopausal women (n = 404) receiving ZOL (IV 4 mg every 
6 months for 3 years) plus endocrine therapy had stable BMD 
during treatment (P = 0.02) and a substantial improvement in 
BMD (+0.4%) 2 years after therapy completion.9 In contrast, 
BMD decreased during treatment in patients receiving endo-
crine therapy alone (lumbar spine, -11.3%; P , 0.0001) and 
remained below baseline 2 years after completion of therapy. 
Therefore, ZOL prevented bone loss during adjuvant endo-
crine therapy and improved BMD at 5 years, 2 years after 
completion of both endocrine and ZOL treatment.
Together, these studies demonstrate that, although not 
yet approved for this indication, ZOL prevents CTIBL and 
improves BMD in premenopausal women receiving adjuvant 
(endocrine or chemo-) therapy for BC and supports reevalu-
ation of treatment paradigms to potentially include ZOL in 
this patient population. In contrast, there is little evidence 
to support the use of oral BPs in this setting. For example, 
weekly risedronate (35 mg) did not prevent bone loss com-
pared with placebo in premenopausal women undergoing 
chemotherapy for BC (n = 216).41 In addition to CTIBL pre-
vention, emerging data suggest potential benefits with ZOL 
therapy that go beyond prevention of bone loss and include 
potential anticancer benefits and favorable tolerability and 
cost-benefit profiles.42–48
Additional considerations for choice 
of BP: anticancer benefit, safety,  
and cost
In addition to the prevention of CTIBL, several other factors 
influence the choice of antiresorptive therapy in premeno-
pausal women with BC. Of particular interest are potential 
anticancer benefits associated with BPs and treatment safety 
and costs for all antiresorptive therapies. Each of these factors 
may influence patient and physician preference for a given 
antiresorptive therapy.
Anticancer benefit and potential 
mechanism
The primary objective of the ABCSG-12 study was to evalu-
ate the effect of ZOL on disease-free survival (DFS) in pre-
menopausal women receiving adjuvant endocrine therapy for 
early BC. Women with stage 1–2 hormone-receptor-positive 
BC (n = 1803) were randomized to receive endocrine therapy 
(goserelin plus tamoxifen or anastrozole) alone or endocrine 
therapy in combination with ZOL (IV 4 mg every 6 months) 
for 3 years.49 The initial study report at a median follow-up 
of 48 months showed that the addition of ZOL to adjuvant 
endocrine therapy significantly improved DFS by 36% 
(hazard ratio [HR] = 0.64; P = 0.01).49 This effect was main-
tained through the 84-month median follow-up 4 years after 
therapy completion, with DFS improved by 28% with ZOL 
(HR = 0.72; P = 0.014) compared with endocrine therapy 
alone. Furthermore, at the 84-month median follow-up, ZOL 
demonstrated improved overall survival compared with no 
ZOL (HR = 0.63; P = 0.049).50 These data suggest a sustained 
anticancer effect that lasts well beyond the end of therapy.
The observed anticancer activity of ZOL may be mediated 
through its effects on the bone microenvironment and the role 
of this environment in BC progression. Cells from the primary 
tumor released into circulation (circulating tumor cells, CTCs) 
may recolonize their tissues of origin (local relapse) or may 
invade bone or visceral organs (distant relapse). Some of these 
CTCs colonize the bone marrow and are subsequently referred 
to as disseminated tumor cells (DTCs). Notably, BC CTCs 
preferentially colonize the bone marrow because this microen-
vironment supports cancer cell survival and growth,51,52 and 
BC cells in bone may secrete factors that can increase rates 
of bone resorption.3,53 Influencing the bone microenvironment 
with ZOL also may reduce the availability of bone-derived 
growth factors and thus contribute to reduced disease recur-
rences in extraskeletal sites. Indeed, clinical data suggest 
that ZOL reduces the persistence and prevalence of DTCs in 
the bone marrow of patients with BC.54–57 This is clinically 
relevant, as DTCs in the bone marrow may be a source of 
subsequent local and distant relapse; therefore, reducing DTC 
persistence may improve survival.53,58
The effects of ZOL on CTCs combined with the results 
of ABCSG-12 suggest that ZOL may prevent increased 
osteolysis and alter the bone microenvironment to make it 
less conducive for colonization and proliferation of cancer 
cells. However, further study is needed to fully delineate 
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the patient population that could benefit most from ZOL 
therapy. For example, the Adjuvant Zoledronic Acid to 
Reduce Recurrence (AZURE) trial did not show clinical 
benefit (DFS improvement) with ZOL (HR = 0.98; P = 0.79) 
in the overall study population (n = 3360, pre- and post-
menopausal women receiving standard adjuvant systemic 
anticancer therapy alone or in combination with ZOL).59 
However, standard therapy decisions were at the treating 
physician’s discretion. Based on standard practices in the 
United Kingdom during the study, premenopausal women 
with early BC (n = 1503 in AZURE) were unlikely to undergo 
estrogen suppression (as in ABCSG-12), thereby resulting 
in substantial heterogeneity in endocrine hormone levels in 
these patients. Notably, ZOL significantly improved invasive 
DFS (HR = 0.75; P = 0.02) and overall survival (HR = 0.74; 
P = 0.04) in the postmenopausal subset (n = 1041) in AZURE, 
suggesting that the endocrine environment is key to realizing 
DFS benefits with ZOL therapy.59 Intriguingly, subset analy-
ses from ABCSG-12 showed that patients . 40 years of age 
experienced significant DFS benefits with ZOL (n = 1390; 
HR = 0.66; P = 0.013), but patients # 40 years of age did 
not (n = 413; HR = 0.87; P = 0.525).50 This further supports 
the observation from AZURE because ovarian suppression 
is more complete in older than in younger premenopausal 
women.42 Therefore, the potential anticancer activity of ZOL 
may also require a low estrogen environment.
Safety
Another advantage of BPs in general and of ZOL in particular 
is that these agents have a well-defined safety profile, and 
adverse events are typically manageable. Flu-like symptoms 
called acute-phase reactions are the most common adverse 
events associated with N-BPs. However, these reactions gen-
erally diminish with subsequent dosing and can be managed 
with analgesics.13 Renal safety is important for patients with 
cancer receiving ZOL. Because ZOL is cleared through the 
kidneys, renal function should be monitored by measuring 
serum creatinine before each dose.13 However, renal failure 
has not been reported in clinical trials of ZOL in premeno-
pausal women with early BC,60 possibly due to fewer comor-
bidities influencing renal function in this patient population 
compared with older, postmenopausal women with BC.
Osteonecrosis of the jaw (ONJ) is another important 
safety consideration for patients with BC. Indeed, ONJ 
is an uncommon but potentially serious adverse event of 
unknown etiology affecting 1% to 2% of patients with 
advanced BC receiving complex treatment regimens, 
including chemotherapy and antiresorptive therapy 
(ie, BPs or denosumab).31,61 However, the risk of ONJ in 
advanced BC can be minimized by preventive dental care 
before the initiation of N-BP therapy,62 and conservative 
management can lead to its resolution.63 Furthermore, ONJ 
is rare in the adjuvant setting,60,64 and no cases of ONJ have 
been reported in premenopausal women with early BC in 
ABCSG-12 (n = 1803).60
Cost
Costs associated with fractures and antiresorptive agents are 
also important considerations when determining the use of 
these therapies. Indeed, bone fractures in patients with BC 
(advanced or early) are associated with increased health 
care costs.65,66 However, ZOL has been shown to be a cost-
effective treatment option in both the advanced and early BC 
settings for preventing SREs and bone loss and subsequent 
fractures due to bone metastases or CTIBL.43,45,47
Analyses based on ABCSG-12 show that treatment with 
ZOL in combination with endocrine therapy in premeno-
pausal women with early BC is cost-effective.43 Analyses 
based on the assumption that observed DFS benefits with 
ZOL continued beyond the 7-year median follow-up of 
ABCSG-12 showed that the additional costs of ZOL therapy 
were offset by savings in the costs associated with BC recur-
rences. Notably, these analyses showed that ZOL reduced 
costs by $US2127 per patient and increased quality-adjusted 
life-years (QALYs) by 1.63 years.43 Moreover, in analyses 
based on the assumption that DFS benefits with ZOL persist 
only for the duration of ABCSG-12, the additional costs of 
ZOL were partially offset by savings in the costs associ-
ated with BC disease recurrences.43 Importantly, the cost-
effectiveness of adding ZOL to endocrine therapy versus 
endocrine therapy alone (,$US10,000 per QALY gained) 
was substantially below the threshold generally considered 
favorable in the USA (ie, $US50,000 per QALY gained), and 
less than that of other generally accepted oncology therapies. 
These analyses show that ZOL is a cost-effective therapy 
primarily because of improvements in survival and reduced 
risk of disease recurrence.43
Conclusions
Bone health is an important consideration for patients with 
BC in both the adjuvant and metastatic settings. Bone loss 
occurs throughout the BC disease continuum and can result 
in bone-related complications that compromise quality 
of life and treatment adherence with primary anticancer 
therapy. Antiresorptive therapies are critical for preserving 
bone health in all women with BC. To date, ZOL has been 
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examined extensively in pre- and postmenopausal women 
with BC. As with pamidronate and denosumab, ZOL has 
been shown to delay the onset of SREs in patients with bone 
metastases from BC. However, other BPs might be less effec-
tive and, in contrast to the large data pool available for ZOL, 
denosumab has yet to be evaluated in the adjuvant CTIBL 
setting in premenopausal women with BC. In combination 
with primary anticancer therapy, ZOL may improve cancer-
related outcomes in some patient populations. Evidence to 
date suggests that ZOL can effectively preserve BMD in 
premenopausal women receiving endocrine therapy for BC 
and may provide additional anticancer benefits (especially in 
patients undergoing ovarian suppression). Furthermore, ZOL 
has a well-established safety profile and is a cost-effective 
therapy. Overall, the clinical and economic data support the 
use of ZOL in women with BC.
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